RGNCY-0127 (8430 SIX1/EYA2 complex inhibitor )

SOLD OUT!!  E-mail us at info@reagency.co if you are interested in this product.

Compound 8430 reduces SIX1/EYA2 interaction which is involved in breast cancer metastasis.  8430 was shown to partially reverse transcriptional and metabolic profiles mediated by SIX1 over-expression and reversed SIX1 induced TGF-Beta signalling and EMT.  In vivo, 8430 was well tolerated in mice and significantly suppressed breast cancer-associated metastasis without altering primary tumor growth.  This is the first demonstration of the pharmacological inhibition of the SIX1/EYA2 complex is sufficient to inhibit cancer metastasis.  Thus, 8430 is a novel compound that effectively reverses EMT phenotypes suppressing breast cancer metastasis.

Systematic Name:  N-(4-methoxy-3-(morpholinosulfonyl)phenyl)-3-(1H-pyrrol-1-yl)benzamide


Formula:  C22H23N3O5S

Mol Wt: 441.50

Tags: Cancer, Apoptosis, small molecule, breast cancer, TGF, TGFB, TGF beta, RGNCY-0127, 8430, SIX1, EYA2